Fennec Pharmaceuticals (TSX:FRX) Research & Development : C$0.08 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Fennec Pharmaceuticals's Research & Development for the three months ended in Dec. 2023 was C$0.04 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.08 Mil.

Fennec Pharmaceuticals Research & Development Historical Data

The historical data trend for Fennec Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Research & Development Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

7.38

6.54

6.38

4.80

0.08

Fennec Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Research & Development	Get a 7-Day Free Trial															0.16	0.01	0.01	0.02	0.04

Fennec Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.08 Mil.

Fennec Pharmaceuticals (TSX:FRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fennec Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.